We established a diagnostic model to predict acute Mycoplasma pneumoniae （M. pneumonia） infection in elderly Community-acquired pneumonia （CAP） patients. We divided 456 patients into acute and non-acute M. pneumon...We established a diagnostic model to predict acute Mycoplasma pneumoniae （M. pneumonia） infection in elderly Community-acquired pneumonia （CAP） patients. We divided 456 patients into acute and non-acute M. pneumoniae infection groups. Binary logistic regression and receiver operating characteristic （ROC） curves were used to establish a predictive model. The following independent factors were identified： age 〉 70 years; serum cTNT level 〉 0.0S ng/mL; lobar consolidation; mediastinal lymphadenopathy; and antibody titer in the acute phase 〉 1：40. The area under the ROC curve of the model was 0.923 and a score of 2 7 score predicted acute M. pneumoniae infection in elderly patients with CAP. The predictive model developed in this study has high diagnostic accuracy for the identification of elderly acute M. pneumoniae infection.展开更多
Objective: To investigate the association between Mycoplasma pneumoniae (MP) infection and the occurrence of acute coronary syndromes (ACS), and its associated mechanism in ACS development. Methods: A total of 134 pat...Objective: To investigate the association between Mycoplasma pneumoniae (MP) infection and the occurrence of acute coronary syndromes (ACS), and its associated mechanism in ACS development. Methods: A total of 134 patients with confirmed ACS were selected as the ACS group, and another 102 healthy subjects were enrolled as the control group. Serum triglycerides (TG), cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB) were detected using immuno-transmission turbidimetry in the ACS and control groups. An enzyme-linked immunosorbent assay was used to detect MP-specific IgG antibodies in the serum. Results:The MP infection rate in the ACS group was significantly higher than that in of the healthy control group. Although there were significant differences in the expression of TC, HDL, LDL, and ApoB between the ACS and control groups, there were no significant differences between the MP IgG-positive and negative groups for any the six serum lipid indexes in the ACS patients. The level of high-sensitivity C-reactive protein (hs-CRP) expression in ACS patients was significantly higher in the MP IgG-positive group compared with the negative group. Conclusions: MP infection is associated with ACS and may be a risk factor for ACS. MP infection may not affect blood lipid levels but rather induce the development of ACS by affecting the long-term inflammatory environment.展开更多
目的探讨不同时期难治性支原体肺炎(refractory mycoplasma pneumoniae pneumonia,RMPP)患儿支气管肺泡灌洗液中表面活性物质相关蛋白-A(surfactant protein A,SPA)的表达水平及与肺功能的关系。方法选取2021年1月—2023年1月南通市第...目的探讨不同时期难治性支原体肺炎(refractory mycoplasma pneumoniae pneumonia,RMPP)患儿支气管肺泡灌洗液中表面活性物质相关蛋白-A(surfactant protein A,SPA)的表达水平及与肺功能的关系。方法选取2021年1月—2023年1月南通市第一人民医院收治的62例RMPP患儿为对象,以同期行支气管镜异物取出术且无肺部感染的50例患儿为对照组。RMPP患儿于急性期、恢复期行支气管肺泡灌洗液中SPA检测以及肺功能指标检测[第1秒用力呼气容积(forced expiratory volume in one second,FEV_(1))、用力肺活量(forced vital capacity,FVC)、FEV_(1)/FVC],对照组同样如此。比较三者检测结果差异,使用Pearson分析RMPP患儿支气管肺泡灌洗液中SPA水平与肺功能指标的相关性。结果RMPP患儿肺泡灌洗液中的SPA急性期(59.82±12.64)μg/L、恢复期(129.91±24.86)μg/L高于对照组,差异有统计学意义(P<0.05)。RMPP急性期、RMPP恢复期的FEV_(1)、FVC、FEV_(1)/FVC(80.95±6.88)%、(88.41±5.75)%较对照组低,差异有统计学意义(P<0.05);RMPP患儿于急性期时肺泡灌洗液中的SPA较恢复期低,FEV_(1)、FVC、FEV_(1)/FVC较恢复期低,差异有统计学意义(P<0.05);RMPP患儿肺泡灌洗液中SPA水平与FEV_(1)、FVC、FEV_(1)/FVC呈正相关(P<0.05)。结论RMPP患儿病情处于急性发展阶段的情况下其支气管肺泡灌洗液中的SPA表达相较病情恢复阶段更低,同时RMPP患儿支气管肺泡灌洗液中SPA水平与其肺功能指标呈正相关性。展开更多
Most patients with COVID-19 disease caused by the SARS-CoV-2 virus recover from this infection, but a significant fraction progress to a fatal outcome. As with some other RNA viruses, co-infection or activation of lat...Most patients with COVID-19 disease caused by the SARS-CoV-2 virus recover from this infection, but a significant fraction progress to a fatal outcome. As with some other RNA viruses, co-infection or activation of latent bacterial infections along with pre-existing health conditions in COVID-19 disease may be important in determining a fatal disease course. Mycoplasma spp. (M. pneumonaie, M. fermentans, etc.) have been routinely found as co-infections in a wide number of clinical conditions, and in some cases this has progressed to a fatal disease. Although preliminary, Mycoplasma pneumoniae has been identified in COVID-19 disease, and the severity of some signs and symptoms in progressive COVID-19 patients could be due, in part, to Mycoplasma or other bacterial infections. Moreover, the presence of pathogenic Mycoplasma species or other pathogenic bacteria in COVID-19 disease may confer a perfect storm of cytokine and hemodynamic dysfunction, autoimmune activation, mitochondrial dysfunction and other complications that together cannot be easily corrected in patients with pre-existing health conditions. The positive responses of only some COVID-19 patients to antibiotic and anti-malaria therapy could have been the result of suppression of Mycoplasma species and other bacterial co-infections in subsets of patients. Thus it may be useful to use molecular tests to determine the presence of pathogenic Mycoplasma species and other pathogenic bacteria that are commonly found in atypical pneumonia in all hospitalized COVID-19 patients, and when positive results are obtained, these patients should treated accordingly in order to improve clinical responses and patient outcomes.展开更多
基金supported by the Capital Medical Development and Scientific Research Fund(2009-1033)and the Science and Technology Plan of Beijing City(Z101107050210018)
文摘We established a diagnostic model to predict acute Mycoplasma pneumoniae （M. pneumonia） infection in elderly Community-acquired pneumonia （CAP） patients. We divided 456 patients into acute and non-acute M. pneumoniae infection groups. Binary logistic regression and receiver operating characteristic （ROC） curves were used to establish a predictive model. The following independent factors were identified： age 〉 70 years; serum cTNT level 〉 0.0S ng/mL; lobar consolidation; mediastinal lymphadenopathy; and antibody titer in the acute phase 〉 1：40. The area under the ROC curve of the model was 0.923 and a score of 2 7 score predicted acute M. pneumoniae infection in elderly patients with CAP. The predictive model developed in this study has high diagnostic accuracy for the identification of elderly acute M. pneumoniae infection.
基金This research was funded by the National Natural Science Foundation of China(31672530)the Science and Technology Project of Henan Province(162300410091).
文摘Objective: To investigate the association between Mycoplasma pneumoniae (MP) infection and the occurrence of acute coronary syndromes (ACS), and its associated mechanism in ACS development. Methods: A total of 134 patients with confirmed ACS were selected as the ACS group, and another 102 healthy subjects were enrolled as the control group. Serum triglycerides (TG), cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB) were detected using immuno-transmission turbidimetry in the ACS and control groups. An enzyme-linked immunosorbent assay was used to detect MP-specific IgG antibodies in the serum. Results:The MP infection rate in the ACS group was significantly higher than that in of the healthy control group. Although there were significant differences in the expression of TC, HDL, LDL, and ApoB between the ACS and control groups, there were no significant differences between the MP IgG-positive and negative groups for any the six serum lipid indexes in the ACS patients. The level of high-sensitivity C-reactive protein (hs-CRP) expression in ACS patients was significantly higher in the MP IgG-positive group compared with the negative group. Conclusions: MP infection is associated with ACS and may be a risk factor for ACS. MP infection may not affect blood lipid levels but rather induce the development of ACS by affecting the long-term inflammatory environment.
文摘目的探讨不同时期难治性支原体肺炎(refractory mycoplasma pneumoniae pneumonia,RMPP)患儿支气管肺泡灌洗液中表面活性物质相关蛋白-A(surfactant protein A,SPA)的表达水平及与肺功能的关系。方法选取2021年1月—2023年1月南通市第一人民医院收治的62例RMPP患儿为对象,以同期行支气管镜异物取出术且无肺部感染的50例患儿为对照组。RMPP患儿于急性期、恢复期行支气管肺泡灌洗液中SPA检测以及肺功能指标检测[第1秒用力呼气容积(forced expiratory volume in one second,FEV_(1))、用力肺活量(forced vital capacity,FVC)、FEV_(1)/FVC],对照组同样如此。比较三者检测结果差异,使用Pearson分析RMPP患儿支气管肺泡灌洗液中SPA水平与肺功能指标的相关性。结果RMPP患儿肺泡灌洗液中的SPA急性期(59.82±12.64)μg/L、恢复期(129.91±24.86)μg/L高于对照组,差异有统计学意义(P<0.05)。RMPP急性期、RMPP恢复期的FEV_(1)、FVC、FEV_(1)/FVC(80.95±6.88)%、(88.41±5.75)%较对照组低,差异有统计学意义(P<0.05);RMPP患儿于急性期时肺泡灌洗液中的SPA较恢复期低,FEV_(1)、FVC、FEV_(1)/FVC较恢复期低,差异有统计学意义(P<0.05);RMPP患儿肺泡灌洗液中SPA水平与FEV_(1)、FVC、FEV_(1)/FVC呈正相关(P<0.05)。结论RMPP患儿病情处于急性发展阶段的情况下其支气管肺泡灌洗液中的SPA表达相较病情恢复阶段更低,同时RMPP患儿支气管肺泡灌洗液中SPA水平与其肺功能指标呈正相关性。
文摘Most patients with COVID-19 disease caused by the SARS-CoV-2 virus recover from this infection, but a significant fraction progress to a fatal outcome. As with some other RNA viruses, co-infection or activation of latent bacterial infections along with pre-existing health conditions in COVID-19 disease may be important in determining a fatal disease course. Mycoplasma spp. (M. pneumonaie, M. fermentans, etc.) have been routinely found as co-infections in a wide number of clinical conditions, and in some cases this has progressed to a fatal disease. Although preliminary, Mycoplasma pneumoniae has been identified in COVID-19 disease, and the severity of some signs and symptoms in progressive COVID-19 patients could be due, in part, to Mycoplasma or other bacterial infections. Moreover, the presence of pathogenic Mycoplasma species or other pathogenic bacteria in COVID-19 disease may confer a perfect storm of cytokine and hemodynamic dysfunction, autoimmune activation, mitochondrial dysfunction and other complications that together cannot be easily corrected in patients with pre-existing health conditions. The positive responses of only some COVID-19 patients to antibiotic and anti-malaria therapy could have been the result of suppression of Mycoplasma species and other bacterial co-infections in subsets of patients. Thus it may be useful to use molecular tests to determine the presence of pathogenic Mycoplasma species and other pathogenic bacteria that are commonly found in atypical pneumonia in all hospitalized COVID-19 patients, and when positive results are obtained, these patients should treated accordingly in order to improve clinical responses and patient outcomes.
